Skip to content
Screener

NovoCure NVCR Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$174.4MIn line
EPS-$0.22Beat by $0.19
Revenue estimate$174.4M
EPS estimate-$0.41

Next report

Oct 29, 2026 (in a month)
Revenue estimate$182.3M
EPS estimate-$0.21

Financials

Q4 2025

Income statement

See full
Revenue$174.4M+8.1%
Gross profit$132.2M+3.4%
Operating income-$40.4M+36.2%
Net income-$24.5M+62.8%
EPS (diluted)-$0.22+63.9%

Balance sheet

See full
Cash & equivalents$93.5M-42.9%
Total debt$53.3M+91.2%
Total equity$340.5M-5.5%
Total assets$804.3M-35.2%

Cash flow

See full
Operating cash flow-$18.0M-422%
CapEx$4.9M-45.2%
Free cash flow-$22.9M-84.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.45B-55.1%
Enterprise value$1.41B-54.4%
P/S2.2×-3.1×

Profitability

See full
Gross margin74.5%-2.8pp
Operating margin-23.5%-3.4pp
Net margin-20.8%-4.2pp
FCF margin-11.5%+0.1pp

Returns & leverage

See full
Return on equity-38.9%-5.6pp
Debt / equity0.2×+0.1×
Current ratio2.9×+1.4×

Segments

By geography

See full
United States$101.6M—
Germany$21.3M—
France$20.3M—
Japan$10.2M—
Greater China$4.6M—

FAQ

When did NovoCure report Q4 2025 earnings?
NovoCure (NVCR) reported Q4 2025 earnings on February 26, 2026 before market open.
What were NovoCure's Q4 2025 revenue and EPS?
NovoCure reported revenue of $174.4M and eps of $-0.22 for Q4 2025.
Did NovoCure beat estimates in Q4 2025?
Revenue missed the consensus estimate of $174.4M by $50.0K. EPS beat the consensus estimate of $-0.41 by $0.19.
How did NovoCure's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 8.1% from $161.3M a year earlier and eps grew 63.9% from $-0.61.
Where can I find NovoCure's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001645113-26-000013) and the 10-K periodic report (0001645113-26-000017) directly on SEC EDGAR. The filing index links above go to sec.gov.